TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35173154
Drug: non-antibiotic treated
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-antibiotic treated infants (control group)
Study: 34480008
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (SB; 0.3 g/kg body mass) with HI warm-up
Study: 34480008
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (SB; 0.3 g/kg body mass) with LI warm-up
Study: 36147018
Drug: CBMT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBMT + TAU (Cognitive Bias Modification Training + Treatment as Usual)
Study: 35212286
Drug: Synbiotics (Bifidobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (Bifidobacterium longum NT strain 1010 CFU/day and galactooligosaccharide 1 g/day)
Study: 32561467
Drug: Narrative Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Exposure Therapy (NET) addressing PTSD
Study: 32561467
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing with cognitive behavioral therapy skills training (MIST) addressing substance misuse
Study: 34330458
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid (UA) supplementation (450 mg/day)
Study: 33048901
Drug: Light sedation
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light sedation with a daily wake‐up call
Study: 36163254
Drug: Methylphenidate (MP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (MP; 60 mg)
Study: 32087001
Drug: Cenobamate single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate single-dose (5 to 750 mg)
Study: 32087001
Drug: Cenobamate multiple-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate multiple-dose (50 to 600 mg/day)
Study: 32087001
Drug: Cenobamate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (all doses)
Study: 32087001
Drug: Cenobamate (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (multiple daily doses of 600 mg)
Study: 36017875
Drug: Obinutuzumab consolidation
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab consolidation therapy
Study: 33587687
Drug: Ad26.ZIKV.001 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZIKV.001 (1 × 10^11 vp, 1-dose regimen)
Study: 616670476
Drug: Volumetric-modulated arc
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volumetric-modulated arc therapy (VMAT)
Study: 33373701
Drug: Paracetamol (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1g intravenous infusion)
Study: 33373701
Drug: Parecoxib (40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40mg intravenous infusion)
Study: 32787809
Drug: Self-management behaviors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management behaviors (medication therapy, diet therapy, exercise, tobacco and alcohol avoidance, stress reduction, self-monitoring/self-care)
Study: 32787809
Drug: Self-management behaviors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management behaviors (diet therapy)
Study: 32787809
Drug: Self-management behaviors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management behaviors (medication therapy)
Study: 35486131
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid in combination with ezetimibe
Study: 35623877
Drug: Morus Alba
Normalized name: MORUS ALBA STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morus Alba extract (300 mg)
Study: 32579195
Drug: Colchicine with
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine with standard medical treatment
Study: 33471547
Drug: Progressive active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive active exercise therapy (PR)
Study: 33471547
Drug: Limited passive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited passive exercise therapy (UC)
Study: 32540337
Drug: Cetuximab consolidation
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab consolidation (500 mg/m2 biweekly × 6)
Study: 32966574
Drug: RBX7455 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX7455 (4 capsules twice daily for 4 days)
Study: 32966574
Drug: RBX7455 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX7455 (4 capsules twice daily for 2 days)
Study: 32966574
Drug: RBX7455 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX7455 (2 capsules twice daily for 2 days)
Study: 35107188
Drug: Colchicine in
Normalized name: colchicine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine in combination with standard care
Study: 34062263
Drug: Polyphenols as
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenols as adjunctive treatments
Study: 32769849
Drug: CMX-2043 (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMX-2043 (2.4 mg/kg)
Study: 36197656
Drug: Completely successful
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completely successful belief about antibiotics
Study: 36197656
Drug: Intermediate belief
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate belief about antibiotics
Study: 33517830
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of influenza vaccine availability
Study: 33517830
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of free influenza vaccine availability
Study: 33517830
Drug: Confidence in
Normalized name: miconazole nitrate Topical Cream [Clearly Confident]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confidence in vaccine efficacy
Study: 33517830
Drug: Confidence in
Normalized name: miconazole nitrate Topical Cream [Clearly Confident]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Confidence in vaccine safety
Study: 32835919
Drug: Fennel seed
Normalized name: FENNEL SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel seed extract (200 mg per capsule, 4 capsules daily for 2 weeks)
Study: 32835919
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules daily for 2 weeks)
Study: 34110580
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate solution (RLS)
Study: 32876695
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg IV daily for 5 days or 10 mg IV daily for 5 days until ICU discharge) plus standard care
Study: 33168504
Drug: Conventional circumcision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional circumcision (CC)
Study: 34556856
Drug: Valsartan (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (320 mg daily in adults; 80-160 mg daily in children)
Study: 35345654
Drug: Dexmedetomidine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine combined intravenous anesthesia
Study: 35345654
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous anesthesia
Study: 32161953
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ketone bodies during a hyperinsulinemic-euglycemic clamp
Study: 32161953
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of saline during a hyperinsulinemic-euglycemic clamp
Study: 34089846
Drug: Lirentelimab (AK002),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lirentelimab (AK002), an antibody against siglec-8 that depletes eosinophils and inhibits mast cells.
Study: 35230440
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy after TURBT
Study: 32028974
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg intravenously on day 1 and gemcitabine 1000 mg/m2 intravenously on days 1 and 8 every 21 days until disease progression or unacceptable toxicity
Study: 32028974
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and gemcitabine combination therapy
Study: 33827091
Drug: 4 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L/min bias gas flow
Study: 33827091
Drug: 10 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 L/min bias gas flow
Study: 32889867
Drug: Sirolimus for
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus for ≥3 months after LT for HCC in patients with AFP ≥10 ng/mL
Study: 33994886
Drug: CN injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CN injection group
Study: 32924553
Drug: Acupuncture Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture Therapy (AT)
Study: 35639946
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (no infiltration, subcutaneous infiltration, rectus sheath infiltration)
Study: 32154936
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus aspirin (90 mg twice daily plus 100 mg once daily)
Study: 32154936
Drug: Ticagrelor alone
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor alone (90 mg twice daily)
Study: 32154936
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (100 mg once daily)
Study: 32475312
Drug: Sodium reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium reduction with slow sodium tablets for 6 weeks
Study: 32475312
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 6 weeks
Study: 34138875
Drug: Group Problem
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Problem Management Plus (PM+), a psychological treatment of 5 weekly sessions
Study: 33357420
Drug: Intravenous pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous pertuzumab (840 mg loading dose, followed by 420 mg maintenance doses) plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg maintenance doses)
Study: 33357420
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses)
Study: 33592837
Drug: Heat patch
Normalized name: CVS Body Heat Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat patch on acupuncture points during the follicular phase (Group C, n=15)
Study: 34475522
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of saracatinib
Study: 34475898
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (NOT) with intravenous Meropenem and Metronidazole for 48 hours followed by oral antibiotics for 7 days (Group A)
Study: 34475898
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (NOT) with failure
Study: 33969450
Drug: UV-irradiated implants
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-irradiated implants
Study: 33969450
Drug: Conventional commercial
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional commercial implants
Study: 35801618
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound (HIFU) treatment by inexperienced physicians
Study: 35801618
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound (HIFU) treatment by experienced physicians
Study: 32345329
Drug: PE +
Normalized name: Chlorpheniramine Maleate/Phenylephrine Hydrochloride 4 MG-10 MG Oral Tablet [SINUS PE + ALLERGY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE + Peer Support (weekly peer calls for 3-4 weeks)
Study: 34125980
Drug: Cigarette smoke
Normalized name: cigarette smoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoke extract (CSE) treatment in 16HBE cells
Study: 33279373
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment (MT)
Study: 33279373
Drug: Dose-reduction/discontinuation (DR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-reduction/discontinuation (DR)
Study: 35442091
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) - multicomponent national child oral health improvement intervention (Childsmile program) excluding nursery FV
Study: 32611327
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant radiotherapy (RT) in addition to standard postoperative treatment of HBV/HCV and nutritional therapy
Study: 32611327
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative treatment of HBV/HCV and nutritional therapy (Control)
Study: 36297080
Drug: L-Citrulline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Citrulline (10 g)
Study: 33993905
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Secukinumab 75 mg, 150 mg, 300 mg)
Study: 35581905
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pioglitazone plus exenatide
Study: 35581905
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy or metformin sequentially followed by glipizide and basal insulin
Study: 33684919
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH (100 μg/kg/day)
Study: 33684919
Drug: Standard-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose GH (33 μg/kg/day)
Study: 33684919
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH (11 μg/kg/day)
Study: 33256192
Drug: Nd:YAG radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG radiation combined with fluoride gel
Study: 34465476
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies against pertussis toxin (PT) measured with the CDC/FDA ELISA
Study: 32446176
Drug: safinamide 50
Normalized name: safinamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 50 mg/day (S50)
Study: 32446176
Drug: safinamide 100
Normalized name: safinamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 100 mg/day (S100)
Study: 34173895
Drug: Supportive counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive counseling (SC) plus Life-Steps medication adherence counseling
Study: 36219589
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention using printed message cards about the quadrivalent HPV vaccine (n = 118)
Study: 32419645
Drug: ColdZyme Mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ColdZyme Mouth Spray
Study: 32419645
Drug: ColdZyme Mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ColdZyme Mouth Spray (good compliance)
Study: 32419645
Drug: ColdZyme Mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ColdZyme Mouth Spray (poor compliance)
Study: 32419645
Drug: ColdZyme Mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ColdZyme Mouth Spray (overall)
Study: 34898069
Drug: Prostatic massage
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostatic massage twice a week (Group A)
Study: 34898069
Drug: Biofeedback and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback and electrical stimulation 5 times a week combined with prostatic massage twice a week (Group C)
Study: 34337917
Drug: As needed
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As needed propofol administration
Study: 34337917
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of propofol (5 mg kg‐1 h‐1)
Study: 33315051
Drug: AKB‐9778 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKB‐9778 (subcutaneous treatment)
Study: 33315051
Drug: Topical ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular AKB‐9778
Study: 33066972
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous iron therapy
Study: 35438278
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2g 8 hourly) for five days
Study: 35438278
Drug: Thiamine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (200 mg 12 hourly) for five days
Study: 36397218
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment (once every other day, 3 times a week for 5 weeks)
Study: 36397218
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medication therapy (control group)
Study: 32452352
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every 2 weeks (ADAQ2W)
Study: 36448974
Drug: Intrathecal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal oxytocin (100 μg)
Study: 34315283
Drug: OPUS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPUS treatment after implementation
Study: 34276366
Drug: Norepinephrine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (0.5 mg/h, maximum 3 mg/h) plus albumin (20–40 g/day)
Study: 34276366
Drug: Midodrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (5 mg three times/day, maximum 12.5 mg three times/day) plus octreotide (100 μg/6 h, maximum 200 μg/6 h) plus albumin (20–40 g/day)
Study: 35065634
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU of OXT vaginal gel daily for eight weeks
Study: 33109148
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion program (biweekly group education sessions and a 12-week individual behavioral modification for oral hygiene course)
Study: 33109148
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion program
Study: 34825740
Drug: PARO robot
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARO robot twice a day (Group 1)
Study: 34108672
Drug: Vedolizumab 600
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab 600 mg
Study: 32108044
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - 500 µg fluticasone propionate twice daily
Study: 32058435
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day (for S. aureus carriers)
Study: 32058435
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day (for noncarriers)
Study: 36352204
Drug: 0.5-mg pramipexole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg pramipexole
Study: 34465833
Drug: Urea +
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea + Biochar (BC) (10 Mg ha-1)
Study: 34465833
Drug: Urea +
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea + Biochar (BC) + Urease Inhibitor (UI) (1 L ton-1)
Study: 34465833
Drug: Biochar (BC)
Normalized name: COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochar (BC) (10 Mg ha-1)
Study: 32755115
Drug: Anti-IL-5 treatments
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-IL-5 treatments (mepolizumab, benralizumab, reslizumab)
Study: 34334142
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention
Study: 34285768
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy sessions (tr‐MI, N = 39)
Study: 34285768
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment as usual (TAU, N = 35)
Study: 34285768
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy sessions (tr‐MI)
Study: 34285768
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment as usual (TAU)
Study: 32267934
Drug: Triglycerides <1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides <1 mmol/L (<89 mg/dL)